Rayno Life Science Portfolio Review:Celera(CRA),Qiagen(QGEN),and Gilead(GILD)
Review of the Laggards Celera (CRA $6.09) has been a laggard primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M in the previous quarter in 2009.Celera has a cumulative loss in the one billion range but the...
Rayno Snow Blog: High and Dry in the West
Did you ski a lot in December? We hope so because January has not delivered much precip since January 2. Mammoth had 13 in on Jan 1 and 2 but scant since that time. Our associate at Big Mountain Resort in Montana complains of rain and fog yesterday but a few flakes may fall today. The culprit...
2011 Review of Rayno Life Science Portfolios Next Week
Stay the Course for Now We will review our holdngs next week and rebalance if necessary. Overall it has been a good week with biotech indices up about 2%. Late January is always a good time for a correction but for now it is "don't fight the FED, don't fight the tape". The large cap laggards...
Microfluidics (MFLU.OB) Acquired for $1.35/Share
Microfluidics announced today that it signed a definitive merger agreement with IDEX Corp.(IEX) for $1.35 net cash to the seller subject to adjustment as provided in the merger agreement. The $1.35 price represents about a 58% premium over recent trading and a 69% premium over volume wieighted...
Rayno Life Science Portfolios: 2011 Movers-Ardea (RDEA),Immucor (BLUD)
We will be attending the JPMorgan Healthcare Conference in San Francisco next week looking for new ideas. Healthcare overall has been a laggard (up 1.87% vs 11.47% S&P for one year period) but subsectors such as diagnostics, tools, large cap drugs and selected biotech stocks have done well...